INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS

Infectious disease is one of the leading cause of significant burden in healthcare industry globally. These disease can also be termed as transmissible disease or communicable disease is caused by various infectious agents including virus, viroids, bacteria, nematodes such as parasitic roundworms and pinworms, arthropods such as ticks, mites, fleas, and lice, fungi such as ringworm, and other macroparasites such as tapeworms and other helminths. Introduction of various technologically advanced diagnosis and treatment option and improvements in hygiene, vaccination, and antimicrobial therapy have decreased the number of deaths caused from infectious diseases. However, emergence and re-emergence of infectious diseases substantially affect the health outcomes of global population.

Global Infectious Disease Therapeutics Market Drivers

Infectious disease therapeutics market is expected to witness significant growth over the forecast period, owing to increasing prevalence of infectious diseases, increasing awareness regarding the early diagnosis of infectious diseases, and increasing research funding activities by various private and government organizations. For instance, according to the National Ambulatory Medical Care Survey: 2015 data findings, 16.8 million visits to physician offices for infectious and parasitic diseases were registered in the U.S. According to the same source, since September 2012, it has been notified that around 2,143 laboratory-confirmed cases of infection with MERS-CoV.

The World Health Organization (WHO) also added that GISRS (Global Influenza Surveillance and Response System) laboratories, from April 2, 2018 to April 15, 2018, tested over 137,071 specimens from various National Influenza centers (NIC) and other national influenza laboratories of 113 countries. Among these collected specimens, around 21,639 were positive for influenza viruses, wherein 12,034 (55.6%) were classified as influenza A and 9,605 (44.4%) as influenza B. According to the Centers for Disease Control and Prevention (CDC), around 5,251 deaths due to influenza infection were registered in the U.S. in 2015. According to the World Health Organization (WHO), in 2015, around 32,000 estimated deaths from tuberculosis and around 3, 23,000 new cases of TB cases were registered in Europe. According to the data published in European Centre for Disease Prevention and Control (ECDC), in February 2018, around 44,000 people die annually from respiratory diseases associated with seasonal influenza in Europe, out of a total of around 6,50,000 global deaths annually.  

Moreover, increasing advancements in rapid diagnosis of various infectious diseases allowing early and quicker diagnosis is greatly impacting the medical outcome of disease treatment. Advanced technologies such as lateral flow, agglutination assays, and solid phase that are used in rapid diagnostics of infectious diseases are integrated with innovative features such as portability of handheld devices, offering point-of-care treatment to the patients. Moreover, advancements in the technology of point-of care diagnostics is expected to drive growth of infectious disease therapeutic market over the forecast period. For instance, in 2014, Becton, Dickinson, and Company offered point-of-care system BD FACSPresto for HIV/AIDS. It offers percentage results of CD4 T lymphocytes and hemoglobin concentration. Moreover, in January 2017, Infectious Disease Research Institute (IDRI) developed a fusion antigen, which is used as a part of diagnostic test manufactured by InBios International, Inc. for Chagas disease.      

Moreover, research funding is provided by various government and private organizations for infectious diseases to provide effective diagnostic and treatment options. For instance, in November 2016, QuantuMDx Group received funding from Bill & Melinda Gates Foundation to develop and test company’s CAPTURE-XT pathogen concentration technology and Q-POC molecular diagnostic platform for rapid low cost detection of tuberculosis. In January 2018, University of Glasgow-led project received US$ 1.85 million funding, which is a part of Global Challenges Research Fund (GCRF). This project will develop new tests for parasitic diseases and rapid testing in remote locations to help enable rapid diagnosis and rapid treatment of infectious diseases.

Global Infectious Disease Therapeutics Market Restraint

Lack of awareness about treatments for disorders, low adoption of treatments, and lack of reimbursement for certain infectious diseases in selected countries are factors that are expected to restrain growth of infectious disease therapeutics market over the forecast period. Moreover, Africa and Asia have high incidence of infectious disorders and low penetration rate of treatments for the same. For instance, according to AVERT, a global HIV and AIDS charity organization based in U.K., in 2015, 6.5 million individuals were infected with Human Immunodeficiency Virus (HIV) in the West and Central African region and around 28% of the HIV infected people were accessing antiretroviral therapy. Furthermore, increasing availability of counterfeit drugs in Asian countries is expected to pose significant threat to the market during the forecast period.    

Infectious Disease Therapeutics Market - Regional Analysis

On the basis of region, global infectious disease therapeutics market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in infectious disease therapeutics market, followed by Europe. North America drive the infectious disease therapeutics market, owing to increasing research and development studies by various government and pharmaceutical organizations about infectious diseases and its diagnosis. Furthermore, high prevalence and awareness of infectious diseases among people, in turn opting for early detection, is expected to drive growth of infectious disease therapeutics market in this region. For instance, according to the Centers for Disease Control and Prevention (CDC), the U.S. reported around 26,203 cases of Lyme disease between 2006 and 2016. According to the same source, around 10,265 deaths were reported due to alcohol-impaired driving crashes in 2015, which accounted for around 29% of all traffic-related deaths in the U.S.

Asia Pacific is expected to witness fastest growth over the forecast period. Rising demand for efficient and quick diagnostic testing, increasing number of strategies adopted by market players to expand their geographical reach in this region, and engagement of government organizations in minimizing the disease burden are factors that are expected to drive market growth in Asia Pacific region. For instance, in March 2013, Qiagen N.V. launched its careHPV test in China. CareHPV is a molecular diagnostic test designed to screen for high risk human papillomavirus (HPV) at low-resource settings such as areas lacking electricity, water or laboratories. Qiagen also gained the approval from China's State Food and Drug Administration (SFDA) for the careHPV in 2012. Moreover, in March 2018, Government of India launched the TB Free India Campaign with an aim to completely eliminate tuberculosis (TB) by 2025.

Infectious Disease Therapeutics Market – Competitive Landscape

Key players operating in the infectious disease therapeutics market include Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceutical, BioCryst Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, Merck & Co., Inc., and Novartis International AG. Key players are developing new products for the treatment of infectious diseases and are also receiving approvals to commercialize their products. For instance, in May 2017, Merck received FDA approval for its ISENTRESS HD, a new 1200 mg integrase inhibitor for HIV-1 infected patients. This drug can also be used in combination therapy with other antiretroviral.

Infectious Disease Therapeutics Market – Taxonomy

The global infectious disease therapeutics market is segmented on the basis of mode of treatment, drug class, disease infection, end user, and region as mentioned below:

By Mode of Treatment

• Drugs
  • Oral Administration
  • Topical
  • Injections
  • Others
• Vaccines

By Drug Class

• Anti-Bacterial
• Anti-Viral
• Anti-Parasite
• Anti-Fungal
• Others

By Disease Indication

• Tuberculosis
• HIV/AIDS
• Influenza
• Hepatitis
• Others

By End User

• Hospital Pharmacy
• Retail Pharmacy
• Others

By Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa